+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the use of JNJ-99245354, a drug given once daily, to see if it helps reduce anxiety better than a placebo when added to existing treatment for people with generalized anxiety disorder GAD. GAD is a mental health condition characterized by uncontrollable and excessive worry about everyday events over a long period. This trial is a phase 3 study focused on treatment effectiveness in patients who have not responded adequately to prior GAD therapies. Participants will be randomly assigned to one of three groups during a double-blind period lasting up to 6 weeks one group receives JNJ-99245354 at dose 1, another at dose 2, and the last group receives a placebo. Following this, eligible participants may enter an open-label phase for up to 24 weeks to receive either dose 1 or dose 2 of JNJ-99245354. Both the study drug and placebo are administered sublingually under the tongue. Throughout the study, participants will be regularly evaluated using anxiety rating scales, including the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression-Severity CGI-S Anxiety Score. Researchers will monitor participants medical stability through physical exams, lab tests, vital signs, and ECGs. The main outcome is the change in anxiety symptoms from baseline to the end of week 6. Safety, tolerability, and longer-term effects will also be assessed during the open-label extension. The total participation may last up to about 30 weeks or more depending on eligibility for the extension phase.

Age: 18Years +All GendersPhase 3
4 locations
P

Actively Recruiting

Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
O

Actively Recruiting

Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.

Age: 18Years - 70YearsAll GendersPhase 3
107 locations
A

Actively Recruiting

Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.

Age: 18Years +All GendersPhase 1
63 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.

Age: 18Years - 70YearsAll GendersPhase 2
40 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of NBI-1065890 compared to a placebo for treating tardive dyskinesia TD in adults. This Phase 2 study focuses on adults aged 18 to 75 with a confirmed diagnosis of TD caused by neuroleptic medication and other related psychiatric conditions such as schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder. The study aims to assess the treatments impact on abnormal involuntary movements and overall improvement. Participants will be randomly assigned to receive either NBI-1065890 or a matching placebo, both taken orally. The study uses a parallel design with quadruple masking to compare the effects over an 8-week period. The main measurement is the change in the Abnormal Involuntary Movement Scale AIMS total score from baseline to week 8, along with secondary assessments of clinical global improvement. During the study, participants will undergo blinded video assessments of their movements, and their responses will be evaluated by expert raters. Researchers will monitor the severity of dyskinesia, psychiatric symptoms, and any side effects. The study includes regular visits over the 8-week treatment period, with safety and tolerability closely observed. Total participation lasts at least 8 weeks, concluding with the final evaluation of movement improvement.

Age: 18Years - 75YearsAll GendersPhase 2
18 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are studying the safety and tolerability of NTR-1011, a fusion protein designed to reduce inflammation by clearing neutrophil extracellular traps, in adults with systemic lupus erythematosus SLE and rheumatoid arthritis RA, as well as in healthy adult volunteers. This Phase 1ab clinical trial aims to determine the highest safe dose of NTR-1011 given either under the skin or intravenously, understand how the body processes the drug, assess immune response to it, and explore early signs of benefit when added to standard treatments. The study has two parts Phase 1a, completed with healthy volunteers receiving single doses of NTR-1011 or placebo via intravenous or subcutaneous routes and Phase 1b, currently recruiting adults with moderate-to-severe SLE or RA who receive five weekly intravenous doses of NTR-1011 alongside their usual care. Dose levels in Phase 1b are adjusted based on safety and response data. No placebo group exists in Phase 1b, and participants are assigned to either the SLE or RA group. Participants undergo physical exams, lab tests, vital sign monitoring, and blood sampling to measure drug levels, immune markers, and antibodies against NTR-1011. Clinical assessments include disease activity scores and patient-reported outcomes specific to SLE and RA. Safety and tolerability are closely monitored throughout treatment and for four weeks after the last dose. The studys findings will help guide future development and dosing of NTR-1011 for autoimmune diseases.

Age: 18Years - 75YearsAll GendersPhase 1
7 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
E

Actively Recruiting

Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.

Age: 50Years +All GendersPhase 3
85 locations

1-10 of 12

1